{"url_path":"/sec/aim/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-028615-index.html","accession_number":"0001493152-26-028615","cik":"0000946644","ticker":"AIM","issuer_name":"AIM ImmunoTech Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-028615-index.html","primary_entity_key":"0000946644","primary_entity_name":"AIM ImmunoTech Inc."},"word_count":294,"has_tables":true,"body_markdown":"** **\n\n**Item\n8.01 Other Events.**\n\n \n\nOn\nJune 15, 2026, AIM ImmunoTech Inc. (the “Company”) issued a press release announcing that on June 12, 2026,\nAIM received a letter from NYSE Regulation confirming that the Company has regained compliance with the continued listing standards\nof the NYSE American LLC (“NYSE American”). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated\nherein by reference.\n\n \n\nThe\nletter stated that the Company is back in compliance with all of the NYSE American continued listing standards set forth in Part 10 of\nthe NYSE American Company Guide (the “Company Guide”). Specifically, the Company resolved the previously identified deficiencies\nunder Section 1003(a)(i), (ii), and (iii) of the Company Guide. As a result, the “below compliance” (“.BC”)\nindicator will be removed from the Company’s trading symbol for its common stock and the Company will be taken off NYSE American’s\nlist of noncompliant issuers on its website. The Company will remain subject to NYSE American’s continued listing monitoring procedures\nand remains committed to maintaining strong financial discipline and governance going forward.\n\n \n\n**Cautionary\nNote Regarding Forward-Looking Statements**\n\n \n\nThis\nCurrent Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended\n(the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).\nThese statements are subject to risks and uncertainties that\ncould cause actual results to differ materially, including but not limited to risks related to NYSE\ncompliance, clinical development, regulatory approval,\nand other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual\nReport on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking\nstatements."}